Media · Investor relations
Investor relations
What we publish for the people who fund, supply and buy from us: the yearly letter, the impact report and the numbers behind both.
2 pieces since 2026
Letters and reports
A straightforward accounting, once a year
We have no obligation to publish a stakeholder letter or an impact report. We do it because the people who fund, supply and buy from us deserve to know how we are holding up our end.
What we published for 2025
2025
ReportAxmed Impact Report 2025
Patients reached, savings delivered and health products shipped in 2025, with the methodology behind every figure and an account of what did not work.
· Axmed · PDF, 15 MB
2025
LetterAxmed Stakeholder Letter 2025
Our progress in 2025, and the trade-offs that come with doing hard things at scale. Written for the people who fund, supply and buy from Axmed.
· Emmanuel Akpakwu
Headline numbers
The year in numbers, as we publish them
Each figure carries its year. The impact page shows how it was counted and how it compares with the year before.
- 4.2M
- patients reached
- 2025 · +453% vs 2024
- 35%
- average cost savings
- 2025 · 22% median
- 130+
- active procurers and suppliers
- 5,000+
- medicines and health products
- 10+ therapeutic areas
- 1,800+
- metric tons shipped
- 2025
- 54
- deals completed
- 2025
Milestones
From incorporation to today
The company as it was built, in the order it happened.
- Aug 2023Incorporated as a U.S. Public Benefit Corporation
- Oct 2023Gates Foundation partnership on maternal, newborn and child health access
- May 2024Seed funding from Founderful
- Jul 2024Global Health Advisory launched
- Sep 2024First one-ton shipment delivered
- Oct 2024Norrsken impact/100; marketplace beta
- Dec 2024Kenya incorporation; East Africa hub opens in Nairobi
- Jan 2025Marketplace open release
- Feb 2025First Axmed Access Summit, Nairobi
- May 2025$5M MNCH Matching Fund launched
- Jul 202525M+ doses shipped
Investor and partner enquiries
For the letter, the report or a conversation: info@axmed.com.